Unknown

Dataset Information

0

Molecular sequelae of proteasome inhibition in human multiple myeloma cells.


ABSTRACT: The proteasome inhibitor PS-341 inhibits IkappaB degradation, prevents NF-kappaB activation, and induces apoptosis in several types of cancer cells, including chemoresistant multiple myeloma (MM) cells. PS-341 has marked clinical activity even in the setting of relapsed refractory MM. However, PS-341-induced apoptotic cascade(s) are not yet fully defined. By using gene expression profiling, we characterized the molecular sequelae of PS-341 treatment in MM cells and further focused on molecular pathways responsible for the anticancer actions of this promising agent. The transcriptional profile of PS-341-treated cells involved down-regulation of growth/survival signaling pathways, and up-regulation of molecules implicated in proapoptotic cascades (which are both consistent with the proapoptotic effect of proteasome inhibition), as well as up-regulation of heat-shock proteins and ubiquitin/proteasome pathway members (which can correspond to stress responses against proteasome inhibition). Further studies on these pathways showed that PS-341 decreases the levels of several antiapoptotic proteins and triggers a dual apoptotic pathway of mitochondrial cytochrome c release and caspase-9 activation, as well as activation of Jun kinase and a Fas/caspase-8-dependent apoptotic pathway [which is inhibited by a dominant negative (decoy) Fas construct]. Stimulation with IGF-1, as well as overexpression of Bcl-2 or constitutively active Akt in MM cells also modestly attenuates PS-341-induced cell death, whereas inhibitors of the BH3 domain of Bcl-2 family members or the heat-shock protein 90 enhance tumor cell sensitivity to proteasome inhibition. These data provide both insight into the molecular mechanisms of antitumor activity of PS-341 and the rationale for future clinical trials of PS-341, in combination with conventional and novel therapies, to improve patient outcome in MM.

SUBMITTER: Mitsiades N 

PROVIDER: S-EPMC137891 | biostudies-literature | 2002 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Mitsiades Nicholas N   Mitsiades Constantine S CS   Poulaki Vassiliki V   Chauhan Dharminder D   Fanourakis Galinos G   Gu Xuesong X   Bailey Charles C   Joseph Marie M   Libermann Towia A TA   Treon Steven P SP   Munshi Nikhil C NC   Richardson Paul G PG   Hideshima Teru T   Anderson Kenneth C KC  

Proceedings of the National Academy of Sciences of the United States of America 20021021 22


The proteasome inhibitor PS-341 inhibits IkappaB degradation, prevents NF-kappaB activation, and induces apoptosis in several types of cancer cells, including chemoresistant multiple myeloma (MM) cells. PS-341 has marked clinical activity even in the setting of relapsed refractory MM. However, PS-341-induced apoptotic cascade(s) are not yet fully defined. By using gene expression profiling, we characterized the molecular sequelae of PS-341 treatment in MM cells and further focused on molecular p  ...[more]

Similar Datasets

2012-11-05 | GSE35414 | GEO
2012-11-05 | E-GEOD-35414 | biostudies-arrayexpress
| S-EPMC2947515 | biostudies-other
| S-EPMC6850931 | biostudies-literature
| S-EPMC6026005 | biostudies-literature
| S-EPMC4508135 | biostudies-literature
| S-EPMC3026846 | biostudies-other